L
Lerato Mohapi
Researcher at University of the Witwatersrand
Publications - 48
Citations - 2895
Lerato Mohapi is an academic researcher from University of the Witwatersrand. The author has contributed to research in topics: Population & Tuberculosis. The author has an hindex of 24, co-authored 41 publications receiving 2697 citations.
Papers
More filters
Journal ArticleDOI
Timing of Antiretroviral Therapy for HIV-1 Infection and Tuberculosis
Diane V. Havlir,Michelle A. Kendall,Prudence Ive,Johnstone Kumwenda,Susan Swindells,Sarojini S. Qasba,Anne F Luetkemeyer,Evelyn Hogg,James F. Rooney,Xingye Wu,Mina C. Hosseinipour,Umesh G. Lalloo,Valdilea G. Veloso,Fatuma Some,N. Kumarasamy,Nesri Padayatchi,Breno Santos,Stewart E Reid,James Hakim,Lerato Mohapi,Peter Mugyenyi,Jorge Sanchez,Javier R. Lama,Jean W. Pape,Alejandro Sanchez,Aida Asmelash,Evans Moko,Fred Sawe,Janet Andersen,Ian Sanne +29 more
TL;DR: In persons with CD4+ T-cell counts of less than 50 per cubic millimeter, earlier ART was associated with a lower rate of new AIDS-defining illnesses and death, as compared with later ART.
Journal ArticleDOI
Maraviroc versus Efavirenz, Both in Combination with Zidovudine-Lamivudine, for the Treatment of Antiretroviral-Naive Subjects with CCR5-tropic HIV-1 Infection
David A. Cooper,Jayvant Heera,James Goodrich,Margaret Tawadrous,Michael S. Saag,Edwin DeJesus,Nathan Clumeck,Sharon Walmsley,Naitee Ting,Eoin Coakley,Jacqueline D. Reeves,Gustavo Reyes-Teran,Mike Westby,Elna van der Ryst,Prudence Ive,Lerato Mohapi,Horacio Mingrone,Andrzej Horban,Frances Hackman,John F. Sullivan,Howard Mayer +20 more
TL;DR: In a post hoc reanalysis excluding 107 patients (15%) with non-R5 screening virus by the current, more sensitive tropism assay, the lower bound of the 1-sided 97.5% confidence interval for the difference between treatment groups was above 10% for each end point as mentioned in this paper.
Journal ArticleDOI
Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002–2007
Morna Cornell,Anna Grimsrud,Lara Fairall,Matthew P. Fox,Gilles van Cutsem,Janet Giddy,Robin Wood,Hans Prozesky,Lerato Mohapi,Claire Graber,Matthias Egger,Andrew Boulle,Landon Myer +12 more
TL;DR: Numbers on ART have increased rapidly in South Africa, but the programme has experienced deteriorating patient retention over time, particularly due to apparent LTFU, and new strategies are needed to improve monitoring of outcomes and maximize retention in care with increasing programme size.
Journal ArticleDOI
Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort.
Jonathan E. Golub,Paul Pronyk,Paul Pronyk,Lerato Mohapi,Nkeko Thsabangu,Mosa Moshabela,Helen Struthers,Glenda Gray,James McIntyre,Richard E. Chaisson,Neil A. Martinson,Neil A. Martinson +11 more
TL;DR: Tuberculosis risk is significantly reduced by IPT in HAART-treated adults in a high-incidence operational setting in South Africa and calls for the implementation of IPt in conjunction with the roll-out of HAART are strengthened.
Journal ArticleDOI
Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study.
Mark A. Boyd,N. Kumarasamy,Cecilia L. Moore,Chidi Nwizu,M. H. Losso,Lerato Mohapi,Allison Martin,Stephen J. Kerr,Annette H. Sohn,Hedy Teppler,O Van De Steen,J-M Molina,Sean Emery,David A. Cooper +13 more
TL;DR: The raltegravir regimen was no less efficacious than the standard of care and was safe and well tolerated, fulfilling the criterion for non-inferiority.